• Ocuphire to Participate in March Investor Conferences

    Источник: Nasdaq GlobeNewswire / 04 мар 2021 08:27:09   America/New_York

    HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9th
    Oppenheimer Healthcare Conference at 9:20 am ET on March 18th

    FARMINGTON HILLS, Mich., March 04, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that Mina Sooch, President and Chief Executive Officer, will participate in the following conferences in the month of March and invites investors to join by webcast. Please see details below:

    H.C. Wainwright: Global Life Sciences Conference (Virtual)

    Title:Ocuphire Pharma (OCUP) Company Presentation
    Date:Tuesday, March 9th, 2021
    Time:7:00 am Eastern Time
    Presenter:Mina Sooch, CEO
    Webcast:On-demand starting at 7am ET on 3/9

    Oppenheimer 31st Annual Healthcare Conference (Virtual)

    Title:Ocuphire Pharma (OCUP) Company Presentation
    Date:Thursday, March 18th, 2021
    Time:9:20 am Eastern Time
    Presenter:Mina Sooch, CEO
    Webcasting Link:https://wsw.com/webcast/oppenheimer9/ocup/2737603

    If you are interested in arranging a one-on-one meeting request, please contact your bank conference representative or ir@ocuphire.com. Presentations are available on the Investors section of Ocuphire’s corporate website in the Events section.

    About Ocuphire Pharma

    Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia, and has been studied in 7 Phase 1 and 2 trials. Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME), and has been studied in 11 Phase 1 and 2 trials. Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia. APX3330 is entering Phase 2 clinical development for DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s completed Phase 2 clinical trials and ongoing Phase 3 registration trials (NCT04620213 and NCT04638660), Phase 2 trial in presbyopia (NCT04675151) and soon to recruit Phase 2 trial in DR/DME (NCT04692688). For more information, please visit www.ocuphire.com.

    Forward Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Ocuphire’s product candidates, results of ongoing and future clinical trials, and commercialization and market opportunities. These forward-looking statements are based upon Ocuphire’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, (vii) changes in market opportunities, (viii) the effects of COVID-19 on clinical programs and business operations, and (ix) the success and timing of commercialization of any of Ocuphire’s product candidates. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Ocuphire Contacts

    Mina Sooch, President & CEO 
    Ocuphire Pharma, Inc. 
    ir@ocuphire.com
    www.ocuphire.com 

    Corey Davis, Ph.D.
    LifeSci Advisors
    cdavis@lifesciadvisors.com


    Primary Logo

Опубликовать